A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease - PubMed (original) (raw)
. 1998 Nov 19;339(21):1506-14.
doi: 10.1056/NEJM199811193392104.
Affiliations
- PMID: 9819449
- DOI: 10.1056/NEJM199811193392104
Free article
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
D Hasenclever et al. N Engl J Med. 1998.
Free article
Abstract
Background: Two thirds of patients with advanced Hodgkin's disease are cured with current approaches to treatment. Prediction of the outcome is important to avoid overtreating some patients and to identify others in whom standard treatment is likely to fail.
Methods: Data were collected from 25 centers and study groups on a total of 5141 patients treated with combination chemotherapy for advanced Hodgkin's disease, with or without radiotherapy. The data included the outcome and 19 demographic and clinical characteristics at diagnosis. The end point was freedom from progression of disease. Complete data were available for 1618 patients; the final Cox model was fitted to these data. Data from an additional 2643 patients were used for partial validation.
Results: The prognostic score was defined as the number of adverse prognostic factors present at diagnosis. Seven factors had similar independent prognostic effects: a serum albumin level of less than 4 g per deciliter, a hemoglobin level of less than 10.5 g per deciliter, male sex, an age of 45 years or older, stage IV disease (according to the Ann Arbor classification), leukocytosis (a white-cell count of at least 15,000 per cubic millimeter), and lymphocytopenia (a lymphocyte count of less than 600 per cubic millimeter, a count that was less than 8 percent of the white-cell count, or both). The score predicted the rate of freedom from progression of disease as follows: 0, or no factors (7 percent of the patients), 84 percent; 1 (22 percent of the patients), 77 percent; 2 (29 percent of the patients), 67 percent; 3 (23 percent of the patients), 60 percent; 4 (12 percent of the patients), 51 percent; and 5 or higher (7 percent of the patients), 42 percent.
Conclusions: The prognostic score we developed may be useful in designing clinical trials for the treatment of advanced Hodgkin's disease and in making individual therapeutic decisions, but a distinct group of patients at very high risk could not be identified on the basis of routinely documented demographic and clinical characteristics.
Comment in
- Prognostic factors in advanced Hodgkin's disease--can they guide therapeutic decisions?
Brice P. Brice P. N Engl J Med. 1998 Nov 19;339(21):1547-9. doi: 10.1056/NEJM199811193392111. N Engl J Med. 1998. PMID: 9819456 No abstract available. - Prognostic score for Hodgkin's disease.
Jack FR, Angus B, Taylor PR. Jack FR, et al. N Engl J Med. 1999 Apr 22;340(16):1288-9; author reply 1289-90. doi: 10.1056/nejm199904223401615. N Engl J Med. 1999. PMID: 10215496 No abstract available. - Prognostic score for Hodgkin's disease.
Watine J. Watine J. N Engl J Med. 1999 Apr 22;340(16):1289-90. N Engl J Med. 1999. PMID: 10215497 No abstract available.
Similar articles
- [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY. Fu XH, et al. Ai Zheng. 2006 Aug;25(8):1013-8. Ai Zheng. 2006. PMID: 16965685 Chinese. - Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Fermé C. Brice P, et al. Cancer. 1996 Sep 15;78(6):1293-9. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W. Cancer. 1996. PMID: 8826953 - Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study.
Fermé C, Bastion Y, Brice P, Lederlin P, Diviné M, Gabarre J, Assouline D, Ferrant A, Berger F, Lepage E. Fermé C, et al. Cancer. 1997 Sep 15;80(6):1124-33. Cancer. 1997. PMID: 9305714 Clinical Trial. - Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review. - [Prognostic factors in Hodgkin and non-Hodgkin lymphomas].
Cuenca X, Xhaard A, Mounier N. Cuenca X, et al. Bull Cancer. 2009 Apr;96(4):461-73. doi: 10.1684/bdc.2009.0844. Bull Cancer. 2009. PMID: 19357020 Review. French.
Cited by
- Real-world treatment outcomes for Hodgkin lymphoma in South Africa: a prospective observational study.
Vogt SL, Laudin G, Zahurak M, Vaughan J, Lakha A, Pather S, Waja Z, Chetty D, Omar T, Stevens W, Ashmore P, Otwombe K, Hlongwane K, Varadhan R, Patel M, Ambinder RF, Martinson NA, Xian RR, Philip V. Vogt SL, et al. Infect Agent Cancer. 2024 Sep 27;19(1):46. doi: 10.1186/s13027-024-00612-4. Infect Agent Cancer. 2024. PMID: 39334203 Free PMC article. - Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD.
Cellini A, Cavarretta CA, Angotzi F, Ruocco V, Serafin A, Danesin N, Pizzi M, Gregianin M, Vio S, Crimì F, Vianello F, Piazza F, Trentin L, Visentin A. Cellini A, et al. Front Oncol. 2024 Sep 5;14:1419118. doi: 10.3389/fonc.2024.1419118. eCollection 2024. Front Oncol. 2024. PMID: 39301543 Free PMC article. - Predictive value of prognostic nutritional index as prognostic biomarkers in patients with lymphoma: a systematic review and meta-analysis.
Liu X, Duan Y, Wang Y, Zhang X, Lv H, Li Q, Qiao N, Meng H, Lan L, Liu X, Liu X. Liu X, et al. Clin Transl Oncol. 2024 Sep 1. doi: 10.1007/s12094-024-03687-y. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39217595 Review. - Analysis by TeloView® Technology Predicts the Response of Hodgkin's Lymphoma to First-Line ABVD Therapy.
Knecht H, Johnson N, Bienz MN, Brousset P, Memeo L, Shifrin Y, Alikhah A, Louis SF, Mai S. Knecht H, et al. Cancers (Basel). 2024 Aug 10;16(16):2816. doi: 10.3390/cancers16162816. Cancers (Basel). 2024. PMID: 39199588 Free PMC article. - SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study.
Vicelić Čutura L, Vujčić M, Galušić D, Blaslov V, Petrić M, Miljak A, Lozić M, Benzon B, Vukojević K, Bubić T, Kunac N, Zjačić Puljiz D, Delić Jukić IK, Križanac M, Lozić B. Vicelić Čutura L, et al. Cells. 2024 Aug 8;13(16):1323. doi: 10.3390/cells13161323. Cells. 2024. PMID: 39195213 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical